IDH2 and central nervous system cancer: Sequencing studies from adult low-grade gliomas have revealed point mutations in the active sites of the IDH1 and IDH2 metabolic enzymes that bestow a novel enzymatic function of reducing alpha-ketoglutarate to the oncometabolite 2-hydroxyglutarate (2-HG)1.